Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,276 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Terminated Not applicable Interventional Results available

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929
View directory record Official record
Conditions
Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions
Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine

NCT00844207
View directory record Official record
Conditions
Malaria
Interventions
Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2009 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

NCT00372775
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Norwalk, Connecticut • Cocoa Beach, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

NCT00002112
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Understanding Disparities in Quitting in African American and White Smokers

NCT01836276
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline
Drug
Lead sponsor
Nikki Nollen, PhD, MA
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

NCT03637491
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avelumab, Binimetinib, Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

NCT03405818
View directory record Official record
Conditions
Onychomycosis, Tinea Unguium
Interventions
Tavaborole 5% Topical Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
72 Months to 203 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Madera, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

NCT03727750
View directory record Official record
Conditions
ECG, Pharmacokinetics, Safety
Interventions
Gemtuzumab Ozogamicin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Healthy Volunteer Positron Emission Tomography Study

NCT00730990
View directory record Official record
Conditions
Healthy
Interventions
Positron Emission tomography, PET Scan with PF-03654746
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 26, 2026, 5:38 PM EDT
Not listed Phase 2 Interventional

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

NCT00031018
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Aricept, IFN-alpha2A
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

NCT00669110
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 26, 2026, 5:38 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT06072196
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older · Male only
Enrollment
3,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 26, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Encorafenib, Cetuximab, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of Axitinib in Advanced Carcinoid Tumors

NCT01435122
View directory record Official record
Conditions
Carcinoid Tumor
Interventions
Axitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

NCT06897683
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-07220060, Carbamazepine ER Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

NCT00615056
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab (avastin), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
61
States / cities
Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

NCT03351751
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, PF-06372865
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 26, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

NCT00823979
View directory record Official record
Conditions
HIV-1
Interventions
UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Pneumococcal Vaccine in Healthy Infants

NCT00205803
View directory record Official record
Conditions
Healthy Subjects, Pneumococcal Infections
Interventions
13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 26, 2026, 5:38 PM EDT
Completed No phase listed Observational Results available

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

NCT00414661
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
21
States / cities
Gilbert, Arizona • Tucson, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 26, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 26, 2026, 5:38 PM EDT